ライフサイエンスコーパス: haemopoietic

1 Novel analogues of EPO are devoid of haemopoietic activity but still possess protective prope

2 questions the significance of studies in non-haemopoietic and differentiation blocked haemopoietic ce

3 eadily reverted the transformed phenotype of haemopoietic and fibroblast cell lines that express the

4 (siglecs) are expressed predominantly in the haemopoietic and immune systems and exhibit specificitie

5 Autologous CD34-positive haemopoietic bone-marrow stem cells were transduced ex v

6 f the kinase domain, potently transforms the haemopoietic cell line FDC-P1 yet prevents Rat-2 fibrobl

7 ure sensitive Bcr-Abl PTK in the multipotent haemopoietic cell line FDCP-Mix for short periods result

8 By transfecting the multipotent haemopoietic cell line FDCP-Mix with a temperature sensi

9 okine showed any similarities, we employed a haemopoietic cell line, TonB210, engineered for inducibl

10 cripts were assayed in human umbilical blood haemopoietic cell lineages.

11 Very few maternal cells expressed the haemopoietic cell marker CD45.

12 In addition to flow cytometric analyses of haemopoietic cell markers, we analysed the hES cell-deri

13 The CD45 antigen is a haemopoietic cell specific tyrosine phosphatase essentia

14 Allogeneic donor CCR5 Delta32 homozygous haemopoietic cell transplantation (HCT) provides the onl

15 de dosing improves outcomes after allogeneic haemopoietic cell transplantation (HCT).

16 ty) conditioning preparative regimens before haemopoietic cell transplantation from an unrelated dono

17 onic graft-versus-host disease (CGVHD) after haemopoietic cell transplantation from an unrelated dono

18 ical and laboratory data of patients who had haemopoietic cell transplantation from Jan 1, 1991, to D

19 nd non-myeloblative preparative regimens for haemopoietic cell transplantation when using unrelated d

20 ts undergoing myeloablative conditioning and haemopoietic cell transplantation would have different m

21 CD45, the leucocyte common antigen, is a haemopoietic cell-specific tyrosine phosphatase.

22 Haemopoietic-cell transplantation (HCT) is an intensive

23 Secretory lysosomes are common to many other haemopoietic cells and also melanocytes.

24 ranscription factor is expressed in immature haemopoietic cells and at key stages during differentiat

25 ourth human chemokine type, derived from non-haemopoietic cells and bearing a new CX3C fingerprint.

26 ll markers, we analysed the hES cell-derived haemopoietic cells by colony-forming assays (for erythro

27 tnatal human neuropoiesis happens, and human haemopoietic cells can transdifferentiate into neurons,

28 Transplantable human haemopoietic cells could serve as a therapeutic source f

29 ablishing chimeric engraftment in hosts with haemopoietic cells derived from an existing hES cell lin

30 eloped a method to generate a broad range of haemopoietic cells from hES-generated embryonic bodies i

31 ory mechanism to transformation of primitive haemopoietic cells is abrogation of response to a growth

32 tion of GATA transcription factors in murine haemopoietic cells was examined by indirect immunofluore

33 ds to efficiently differentiate hES cells to haemopoietic cells, including immune-modulating leucocyt

34 K) in their blast cells compared with normal haemopoietic cells, rendering the cells sensitive to the

35 rucial to the development and functioning of haemopoietic cells, so much so that mouse embryos homozy

36 non-haemopoietic and differentiation blocked haemopoietic cells.

37 this increased abl PTK activity in primitive haemopoietic cells.

38 sion of apoptosis by this cytokine in normal haemopoietic cells.

39 could occur without excessive GVHD in mixed haemopoietic chimeras produced across HLA barriers with

40 Mixed haemopoietic chimerism was established, with a predomina

41 lling theoretical reasons why treatment with haemopoietic colony-stimulating factors might reduce sep

42 ies were further cultured in the presence of haemopoietic cytokines.

43 sufficient to accelerate the onset of clonal haemopoietic disorders usually associated with later lif

44 The kinetics of haemopoietic engraftment impose replicative stress on th

45 is, chronic haemolytic anaemia, compensatory haemopoietic expansion, hypercoagulability, and increase

46 raft parenchymal cells; recognition of donor haemopoietic fraction was not required.

47 ll had severely shortened telomeres, reduced haemopoietic function, and raised serum erythropoietin a

48 d aplastic anemia, both typified by impaired haemopoietic function.

49 after the identification of EPO as the major haemopoietic growth factor determining survival and matu

50 n of proliferation and commitment within the haemopoietic hierarchy.

51 stage the absence of c-Myb blocks the adult haemopoietic lineages.

52 Haemopoietic microchimerism has been identified in recip

53 or other ubiquitous (Spl, c-Jun and TBP) or haemopoietic (NF-E2) transcription factors.

54 ght be an example of transdifferentiation of haemopoietic or stromal progenitor cells.

55 Bone marrow transplantation recreated the haemopoietic phenotype of increased circulating M2 macro

56 c-FMS is expressed in pluripotent haemopoietic precursor cells and is subsequently upregul

57 ic beta-cell function (adipsin p=0.0056) and haemopoietic precursor proliferation (stem cell growth f

58 Haemopoietic progenitor cell (HPC) transplantation can c

59 (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malign

60 PML-RAR alpha fusion protein of APL renders haemopoietic progenitor cells resistant to Fas-, TNF- an

61 ronic myeloid leukaemia (CML), unlike normal haemopoietic progenitor cells, are resistant to the grow

62 rformed on E8.5 yolk sac cells revealed that haemopoietic progenitors are already defective at this s

63 Selective killing of autologous haemopoietic progenitors by the Vbeta-specific lymphocyt

64 timulating factor, mobilise large numbers of haemopoietic progenitors has resulted in the peripheral

65 Cytotoxic T cells and early haemopoietic progenitors share the expression of a numbe

66 in controlling the development of primitive haemopoietic progenitors the identification of the speci

67 priming of expression begins in multipotent haemopoietic progenitors via GATA-2.

68 h elicits an acute leukaemia by transforming haemopoietic progenitors.

69 activity in T cells are similarly active in haemopoietic progenitors.

70 ) is caused by acquired somatic mutations in haemopoietic progenitors.

71 ironment for the development of T cells from haemopoietic progenitors.

72 on the proliferation and survival of normal haemopoietic progenitors.

73 n at lower doses, must be separated from the haemopoietic properties that occur at clinical doses and

74 ed cord blood progenitor cells to accelerate haemopoietic recovery and reduce infections after chemot

75 Monitoring of haemopoietic status in BMT recipients as time since BMT

76 aemia (CML) arises after transformation of a haemopoietic stem cell (HSC) by the protein-tyrosine kin

77 Chronic myeloid leukaemia is a haemopoietic stem cell disorder, the hallmark of which i

78 mal models, the rhesus macaque and the human haemopoietic stem cell reconstituted mouse.

79 Center, WA, USA, who received an allogeneic haemopoietic stem cell transplantation between Jan 1, 20

80 Allogeneic haemopoietic stem cell transplantation can be complicate

81 dysplastic syndrome and two who had received haemopoietic stem cell transplantation had either no res

82 ical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with

83 Non-myeloablative autologous haemopoietic stem cell transplantation in patients with

84 Autologous non-myeloablative haemopoietic stem cell transplantation is a method to de

85 tratified by geographical region, allogeneic haemopoietic stem cell transplantation, and active malig

86 of overall mortality in the first year after haemopoietic stem cell transplantation, independent of t

87 licable to more than one lysosomal disorder (haemopoietic stem cell transplantation, pharmacological

88 l load and mortality in the first year after haemopoietic stem cell transplantation.

89 ty was 30.0% (95% CI 26.9-33.0) 1 year after haemopoietic stem cell transplantation.

90 unosuppressive and biological treatments, or haemopoietic stem cell transplantation.

91 tolerability of autologous non-myeloablative haemopoietic stem cell transplantation.

92 ugs used for initial therapy with or without haemopoietic stem cell transplantation.

93 CML) is a clonal disorder of the pluripotent haemopoietic stem cell, the hallmark of which is the con

94 arget of the aberrant immune response is the haemopoietic stem cell, the triggering antigens remain u

95 us infusion of three doses of CD133-positive haemopoietic stem cells (0.2 x 10(6) cells per kg per in

96 host haemopoiesis before venous infusion of haemopoietic stem cells (HSCs).

97 Some patients treated by transplantation of haemopoietic stem cells (peripheral blood or bone marrow

98 -Abl, promotes the inappropriate survival of haemopoietic stem cells by a nonautocrine mechanism in t

99 Transplantation of allogeneic haemopoietic stem cells can cure several non-malignant d

100 Allogeneic transplantation with haemopoietic stem cells from an HLA-matched related dono

101 bone marrow becoming the preferred source of haemopoietic stem cells in autologous, and increasingly

102 Clinical experience from use of adult haemopoietic stem cells in haematology will facilitate a

103 Transplantation of haemopoietic stem cells is an increasingly important app

104 End-organ repair by adult haemopoietic stem cells is under great scrutiny with inv

105 The conditioning regimen for the haemopoietic stem cells was 200 mg per kg cyclophosphami

106 Peripheral blood haemopoietic stem cells were mobilised with 2 g per m2 c

107 We mobilised autologous haemopoietic stem cells with 2.0 g/m2 cyclophosphamide a

108 ect the process (ie, clonal proliferation of haemopoietic stem cells with a mutant phosphatidylinosit

109 engraftment impose replicative stress on the haemopoietic stem cells, resulting in a pronounced agein

110 role in the mobilisation and homeostasis of haemopoietic stem cells.

111 ts (BMT) involves extensive proliferation of haemopoietic stem cells.

112 The combination had no effect on normal haemopoietic stem cells.

113 ctive lymphocytes mediate the destruction of haemopoietic stem cells.

114 anaemia is caused by an intrinsic defect of haemopoietic stem cells; both inherited and acquired for

115 se-intense immune suppression and autologous haemopoietic stem-cell (CD34) infusion.

116 Aplastic anaemia is a rare haemopoietic stem-cell disorder that results in pancytop

117 Autologous CD34 selected haemopoietic stem-cell grafts were collected after mobil

118 INTERPRETATION: G-CSF with or without haemopoietic stem-cell infusion did not improve liver dy

119 fficacy of immune suppression and autologous haemopoietic stem-cell infusion to treat such patients.

120 locyte colony-stimulating factor (G-CSF) and haemopoietic stem-cell infusions in patients with liver

121 High-dose chemotherapy with haemopoietic stem-cell rescue improves event-free surviv

122 loablation (with 200 mg/m2 of melphalan) and haemopoietic stem-cell rescue.

123 associated with a uniform reduced intensity haemopoietic stem-cell transplant (HSCT) regimen for chi

124 previous bendamustine-containing regimen, or haemopoietic stem-cell transplant were also excluded.

125 -depleting antibodies followed by autologous haemopoietic stem-cell transplantation (aHSCT), has been

126 omegalovirus (CMV) and undergoing allogeneic haemopoietic stem-cell transplantation (HCT) are at risk

127 ry acute myeloid leukaemia before allogeneic haemopoietic stem-cell transplantation (HCT).

128 antation collected data for the evolution of haemopoietic stem-cell transplantation (HSCT) activity a

129 Autologous haemopoietic stem-cell transplantation (HSCT) benefits p

130 Haemopoietic stem-cell transplantation (HSCT) eradicates

131 Autologous haemopoietic stem-cell transplantation (HSCT) improves s

132 In chronic granulomatous disease allogeneic haemopoietic stem-cell transplantation (HSCT) in adolesc

133 Non-randomised studies of haemopoietic stem-cell transplantation (HSCT) in systemi

134 (GVHD) is the major limitation of allogeneic haemopoietic stem-cell transplantation (HSCT), for which

135 virus-seropositive patients after allogeneic haemopoietic stem-cell transplantation (HSCT), mainly du

136 his trial and after treatment and subsequent haemopoietic stem-cell transplantation (HSCT).

137 cancer and those who have had an allogeneic haemopoietic stem-cell transplantation (HSCT).

138 se of non-relapse mortality after allogeneic haemopoietic stem-cell transplantation (SCT).

139 n, relapse within 12 months after allogeneic haemopoietic stem-cell transplantation [HSCT], or no res

140 andidates for reduced-intensity conditioning haemopoietic stem-cell transplantation and had an availa

141 upportive care should improve the success of haemopoietic stem-cell transplantation for high-risk pat

142 with intensive chemotherapy, with or without haemopoietic stem-cell transplantation in first complete

143 therapy, and to assess the effectiveness of haemopoietic stem-cell transplantation in patients with

144 related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation is safe and is as

145 Allogeneic haemopoietic stem-cell transplantation is the only exist

146 g, twice a day) was initiated 10 days before haemopoietic stem-cell transplantation until day 100.

147 ) units provide the potential for successful haemopoietic stem-cell transplantation.

148 or prevention of GVHD in broader settings of haemopoietic stem-cell transplantation.

149 ophils and platelets at expected times after haemopoietic stem-cell transplantation.

150 related-donor reduced-intensity conditioning haemopoietic stem-cell transplantation.

151 to more widespread application of allogeneic haemopoietic stem-cell transplantation.

152 Even patients with unrelated donor haemopoietic stem-cell transplants had adequate engraftm

153 with suitable donors are offered allogeneic haemopoietic-stem-cell transplant.

154 derstanding of the roles of c-Myb beyond the haemopoietic system and to our knowledge and means of in

155 n in proliferative deficiencies of the human haemopoietic system, and discuss the potential use of te

156 ve multi- and uni-lineage progenitors of the haemopoietic system.

157 ronchus, trachea, bladder, and lymphatic and haemopoietic systems was lowered.

158 m antigen-specific lymphocyte attack against haemopoietic tissue, we analysed effector immunity, seek

159 Haemopoietic tissues exposed to ionizing radiation are s

160 or myeloid lineage can be detected in adult haemopoietic tissues.

161 tive donor stem-cell engraftment without non-haemopoietic toxicity.

162 GATA-1 is a key haemopoietic transcription factor whose activity is incr